VJHemOnc Podcast cover image

Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!

VJHemOnc Podcast

00:00

Promising Advances in BPDCN Treatment: Insights from the Cadenza Trial

This chapter highlights promising research findings from the Cadenza trial on the CD123 antibody drug conjugate, Pavecimab Sunarine, showcasing a 70% complete remission rate. It also discusses future strategies for treating BPDCN, including BCL2 targeting and combination therapies.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app